17,261 trials
Asthma
Primary: Change From Period Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1) — 0.081; 0.049; -0.083 liters — p=0.001
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Number of Participants With Confirmed Tumor Response Defined to be Either a Complete Response (CR) or Partial Response (PR) — 0; 0 participants
Distal Urethral Cancer · Proximal Urethral Cancer · Recurrent Bladder Cancer
Primary: Best Tumor Response (Complete [CR] or Partial Response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST]) — 0; 0 participants
ALPS · Hypersplenism · Lymphadenopathy
Primary: Number of Participants With Response — 0 participants
de Novo Myelodysplastic Syndromes · Previously Treated Myelodysplastic Syndromes · Secondary Myelodysplastic Syndromes
Primary: Number of Confirmed Responses (Complete Response, Partial Response, or Hematologic Improvement) Noted on 2 Consecutive Evaluations at Least 4 Weeks Apart — 1; 0; 0…
Head and Neck Neoplasms
Primary: Progression Free Survival (PFS) — 4.4 months
Kidney Cancer · Renal Cell Carcinoma
Primary: Median Time to First Skeletal-related Event — 9 months
Gastroesophageal Reflux Disease (GERD)
Primary: Number of Participants With at Most One Day With Not More Than Mild Intensity of the Symptoms 'a Burning Feeling Behind the Breastbone' and 'Unpleasant Movement of…
Nicotine Dependence
Primary: Biochemically Verified 7-day Point Prevalence Abstinence at the End of 8 Weeks of Treatment — 10; 13 participants
Breast Neoplasms
Primary: Overall Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST) — 0; 0; 10.2; 14.3 percentage of participants
Glioblastoma · Gliosarcoma
Primary: 12-month Progression Free Survival (PFS) — 43.8; 34.4 percentage of participants
Constipation
Primary: Change of Mean Weekly Spontaneous Bowel Movements — 2; 2; 2; 2 stools/week — p=0.238
Cystic Fibrosis
Primary: Change in the Logarithm of the Level of Human Neutrophil Elastase (HNE) Activity Measured in Sputum — 0.03; -0.17 log10 mcg/mL — p=0.14
Methamphetamine Dependence
Primary: Clean Urine Drug Screen — 13.1; 12.7 Clean urine drug screens
Carcinoma, Renal Cell
Primary: Progression-free Survival (PFS) — 8.4; 11.1 Months